Artia Global Partners LP Makes New Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Artia Global Partners LP acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 102,900 shares of the company’s stock, valued at approximately $2,315,000. Enliven Therapeutics comprises about 0.8% of Artia Global Partners LP’s portfolio, making the stock its 20th largest holding. Artia Global Partners LP owned about 0.21% of Enliven Therapeutics at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ELVN. Tower Research Capital LLC TRC lifted its holdings in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Enliven Therapeutics in the fourth quarter worth about $97,000. ExodusPoint Capital Management LP purchased a new position in shares of Enliven Therapeutics in the fourth quarter worth approximately $200,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 14.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock valued at $233,000 after acquiring an additional 1,275 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Enliven Therapeutics by 17.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company’s stock valued at $307,000 after acquiring an additional 1,980 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 21st.

Insider Buying and Selling at Enliven Therapeutics

In related news, COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $21.93, for a total transaction of $146,207.31. Following the transaction, the chief operating officer now owns 329,977 shares of the company’s stock, valued at approximately $7,236,395.61. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $16.07, for a total transaction of $80,350.00. Following the completion of the sale, the insider now directly owns 997,688 shares of the company’s stock, valued at $16,032,846.16. This represents a 0.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,751 shares of company stock worth $1,340,713 over the last 90 days. 29.20% of the stock is currently owned by corporate insiders.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $18.21 on Friday. The company has a market capitalization of $892.36 million, a price-to-earnings ratio of -9.58 and a beta of 1.03. The business’s 50-day moving average is $19.37 and its 200-day moving average is $22.67. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million for the quarter. Equities research analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.